DNA Vectors
Our Vector in a Nutshell
Introduction:
Which delivery system is better? The "battle" between proponents of viraland non-viral vectors is less a confrontation and more an evolution of two approaches that address their unique challenges. The answer to this question is clear - each tool is suitable for its purpose. The flexibility and safety of non-viral vectors are ideal where targeted delivery, prolonged but limited expression period of the target protein, and minimal risks are essential.
Our Unique Value Proposition
We have refined the non-viral vector approach to address its traditional drawbacks, prioritizing safety and efficiency. Our proprietary vector offers four key innovations:
-
Enhanced Safety: By eliminating antibiotic resistance genes, we minimize potential risks;
-
Viral-Element Free: No viral components are included in the construct, further boosting overall safety;
-
Optimized Vector Design: A smaller vector length ensures more efficient gene delivery;
-
Industrial-Scale Production: The construction is readily scalable, supporting robust and cost-effective manufacturing.
Type | Viral vectors (lentivirus) | Viral vectors (retrovirus) | "Sleeping Beauty" non-viral system (transposon/transposase) | Existing vector plasmids | mRNA | Non-viral Gene therapy VTvaf17 and GDTT1.8NAS series vectors |
|---|
The Vector Development
Our Non-Viral DNA Vector: VTvaf17
-
Patent Protection
A dedicated patent has been filed to safeguard VTvaf17’s intellectual property.
-
Proven Safety
Toxicology tests confirm a favorable safety profile with minimal side-effect risk.
-
Global Compliance
Strains have been deposited in an international repository under the Budapest Treaty of 1977.
-
Universal Applicability
VTvaf17 can carry and deliver virtually any gene combinations, making it highly versatile for therapeutic development.
Strains used for the Vector Development:
The Escherichia coli SCS 110-AF strain serves as the basis for VTvaf17. This strain carries the target human gene(s) while excluding antibiotic resistance genes, in full compliance with stringent regulatory standards for medicinal product safety.
Patents
RU 2 678 756, International Application Number: РСТ/RU2018/000191, WO2019/039962, USA Application Number: 16636713; Title of Invention: “Gene therapy DNAvector VTvaf17, production method, strain Escherichia coli SCS110-AF, production method, strain Escherichia coli SCS110-AF/ VTvaf17, bearing gene therapy DNA-vector VTvaf17, production method”. Date of invention: 25.08.2017.
More information about patents:
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019039962
Additional Gene Therapy Vectors
Alongside VTvaf17, our group of companies has developed and patented a range of non-viral DNA vectors, all free from viral genomes and antibiotic resistance genes.
These vectors adhere to the same safety-centric principles and can be utilized for a variety of therapeutic and research applications:
-
VTvaf17-Cas9
Enables multiple genome-editing methods in human and animal cells.
-
VTvaf17-Act1-Cas9
Developed for diverse genome-editing approaches in plant cells.
-
GDTT1.8NAS12 (2,591 bp)
A platform solution closely related to VTvaf17, offering similar benefits in safety and efficacy.
-
GDTT1.8NAS1 through GDTT1.8NAS11 (11 distinct vectors)
Designed for tissue-specific expression of target genes in muscle, skin, vascular endothelium, bone tissue, pulmonary tissue (bronchi and alveoli), nerve tissue, kidney podocytes, blood (hematopoietic cells, lymphocytes, or macrophages), and pancreatic beta cells.
Links to Publications of Patents of other our vectors:
Licensing Service:
We offer cost-effective licensing of our proprietary vector technology to external partners. For more information on how to license our vector, please contact us here.
For more information,
see our presentation: download here
